Evidence map›Paper›PMID 22773605›Full record

ReviewHaematologica2013

ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study.

Ilske Oschlies, Jasmin Lisfeld, Laurence Lamant, Atsuko Nakazawa, Emanuele S G d'Amore, Ulrika Hansson, Konnie Hebeda, Ingrid Simonitsch-Klupp, Jadwiga Maldyk, Leonhard Müllauer and 8 more

Open access · goldAbstract readCase ReportsMulticenter StudyReview
In one paragraph

Review in Haematologica, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 125 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Recent advances in cutaneous lymphoma-implications for current and future classifications.Virchows Archiv : an international journal of pathology · 2023
    Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 12 institutions in 8 countries.

Ilske OschliesDepartment of Pathology, Hematopathology Section and Lymph Node Registry, Christian-Albrechts-University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. ioschlies@path.uni-kiel.de
Jasmin Lisfeld
Laurence Lamant
Atsuko Nakazawa
Emanuele S G d'Amore
Ulrika Hansson
Konnie Hebeda
Ingrid Simonitsch-Klupp
Jadwiga Maldyk
Leonhard Müllauer
Marianne Tinguely
Markus Stücker
Marie-Cecile Ledeley
Reiner Siebert
Alfred Reiter
Laurence Brugières
Wolfram Klapper
Wilhelm Woessmann
University of Giessen · DEInstitut Gustave Roussy · FRMedical University of Vienna · ATUniversity of Lübeck · DECentre Hospitalier Universitaire de Toulouse · FRKiel University · DENational Center For Child Health and Development · JPOspedale San Bortolo · ITRadboud University Nijmegen · NLRuhr University Bochum · DESahlgrenska University Hospital · SEUniversity Hospital of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anaplastic large cell lymphomas are peripheral T-cell lymphomas that are characterized by a proliferation of large anaplastic blasts expressing CD30. In children, systemic anaplastic large cell lymphomas often present at advanced clinical stage and harbor translocations involving the anaplastic lymphoma kinase (ALK) gene leading to the expression of chimeric anaplastic lymphoma kinase (ALK)-fusion proteins. Primary cutaneous anaplastic large cell lymphoma is regarded as an ALK-negative variant confined to the skin and is part of the spectrum of primary cutaneous CD30-positive T-cell lymphoproliferative disorders. Thirty-three of 487 pediatric patients registered within the Anaplastic Large Cell Lymphoma-99 trial (1999 to 2006) presented with a skin limited CD30-positive lympho-proliferative disorder. In 23 of the 33 patients, material for international histopathological review was available, and the cases were studied for histopathological, immunophenotypical and clinical features as well as for breaks within the ALK gene. Five of 23 cases and one additional case (identified after closure of the trial) expressed ALK-protein. Complete staging excluded any other organ involvement in all children. Expression of ALK proteins was demonstrated by immunohistochemistry in all cases and the presence of breaks of the ALK gene was genetically confirmed in 5 evaluable cases. The histopathological and clinical picture of these skin-restricted ALK-positive lymphomas was indistinguishable from that of cutaneous anaplastic large cell lymphoma. Five children presented with a single skin lesion that was completely resected in 4 and incompletely resected in one. Three of these patients received no further therapy, 2 additional local radiotherapy, and one chemotherapy. All children remain in complete remission with a median follow up of seven years (range 1-8 years). We present 6 pediatric cases of ALK-positive primary cutaneous anaplastic large cell lymphomas. After thorough exclusion of systemic involvement, therapy confined to local measures seems to be sufficient to induce cure.

Indexed as

AdolescentAnaplastic Lymphoma KinaseBiomarkers, TumorChildFemaleHumansLymphoma, Large-Cell, AnaplasticMaleReceptor Protein-Tyrosine KinasesSkin NeoplasmsALK protein, humanAnaplastic Lymphoma KinaseBiomarkers, TumorReceptor Protein-Tyrosine Kinases

Identifiers

PMID22773605
PMCPMC3533659
OpenAlexW2168488962

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.